Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-91

Extremely impressive when you consider the dosing regimen was not suitable for Bis, and Dox was dosed relentlessly.

I think one of the most vital things to consider is how the mechanisms of action for Bis and Dox differ. I think you get a real-world sense of how the combination is going to play out in humans when you consider that the drugs have broad spectrum mechanisms of action that drive cancer cell death individually while also synergising to more effectively treat cancer. This is further evidenced by the sensitivity assays that demonstrate consistently that Bisantrene is doing something very different to Dox and Mitox. There are P2 combination trials of Mitox/Dox where the cardiotoxicity is huge, so if the addition of Bisantrene to Doxorubicin provides meaningful cardioprotection, then I think we are a serious chance of something massive.